Deerfield Management VTRS Position
ActiveDeerfield Management trimmed their position in Viatris Inc (VTRS) in Q4 2025, holding $251.6M worth of shares across 20,206,170 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
1 other tracked fund also holds VTRS.
About Viatris Inc
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Full company profile →Short Interest
2.8%
2.6 days to cover
Deerfield Management VTRS Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 20,206,170 | -3,892,913 | $251.6M |
| Q3 2025 | Increased | 24,099,083 | +75,176 | $238.6M |
| Q2 2025 | Increased | 24,023,907 | +32,313 | $214.5M |
| Q1 2025 | Decreased | 23,991,594 | -4,442 | $209.0M |
| Q4 2024 | Increased | 23,996,036 | +3,013 | $298.8M |
| Q3 2024 | Increased | 23,993,023 | +2,597,527 | $278.6M |
| Q2 2024 | Increased | 21,395,496 | +444 | $227.4M |
| Q1 2024 | Increased | 21,395,052 | +1,531,568 | $255.5M |
| Q4 2023 | Decreased | 19,863,484 | -1 | $215.1M |
| Q3 2023 | Increased | 19,863,485 | +2,160,001 | $195.9M |
| Q2 2023 | Increased | 17,703,484 | +767,487 | $176.7M |
| Q1 2023 | New | 16,935,997 | +16,935,997 | $162.9M |
Frequently Asked Questions
Does Deerfield Management own VTRS?
Yes. As of Q4 2025, Deerfield Management holds 20,206,170 shares of Viatris Inc (VTRS) valued at $251.6M. This data comes from their SEC 13F filing.
How many hedge funds own VTRS?
2 specialist biotech hedge funds currently hold VTRS, including Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy VTRS?
Deerfield Management's position in VTRS was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's VTRS position increasing or decreasing?
Deerfield Management trimmed their VTRS position in the most recent quarter, reducing by 3,892,913 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
VTRSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →